Nalaganje...
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...
Shranjeno v:
| izdano v: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485066/ https://ncbi.nlm.nih.gov/pubmed/28273356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.876 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|